mavrostobart

Mavrostobart (PT199) is a humanized IgG4κ monoclonal antibody that targets CD73 (also known as NT5E or 5'-nucleotidase). It is designed to completely inhibit the enzymatic activity of CD73, which plays a key role in generating immunosuppressive adenosine within the tumor microenvironment. By blocking CD73, mavrostobart aims to counteract adenosine-mediated immunosuppression and enhance anti-tumor immune responses, particularly in combination with checkpoint inhibitors such as PD-1/PD-L1 inhibitors. The drug is being developed for various advanced solid tumors including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and other malignancies where CD73 is overexpressed. Mavrostobart addresses limitations of previous CD73 inhibitors by offering more complete enzyme inhibition and potential synergy with existing immunotherapies[3][4][6].

Brand names

mavrostobart

Other names

PT199PT-199PT 199mavrostobart